Contract Development Services

The companies will merge to offer a broader range of analytical data packages and regulatory support for biopharmaceuticals.

Catalent’s acquisition of Paragon Bioservices will provide expertise and in expanding gene and cell therapy markets.

The new service offers a flexible, customizable suite of products and services designed to accelerate the clinical and commercial development of gene and cell therapies.

The acquisition of CiVentiChem’s facility in the United States is expected to enhance UK-based Sterling Pharma Solutions’ chemistry development capabilities.

Catalent invests $5 million in hot melt extrusion capabilities at Somerset, NJ facility.

The partnership will enable the Applied Process Company (APC) and the National Institute for Bioprocessing Research & Training (NIBRT) to provide increased access to R&D and analytical services.

More work needed to advance drug design and development effectively.

Catalent announces investment for its Zydis ODT technology, offering increased drug load and taste-masking capabilities.

A $100-million investment will expand a range of the CDMO’s service capabilities and offerings.

The expansion includes a new R&D laboratory and the installation of a 12,000-liter reactor at one of the company’s manufacturing facilities on its Paullo site in Milan, Italy.

Keeping abreast of the latest industry trends and retaining flexibility are key to maintaining a strong market position.

Novel analytical methods may help biologics manufacturers respond to stricter regulations on particulate matter.

Tech transfer is key to succession advancing biopharmaceutical pipeline products from research to preclinical.

Outsourcing of analytical testing and processes can help bio/pharmaceutical companies expand their product profiles.

The company will invest $4 million to increase topical and transdermal formulation development and performance testing services at its Durham, NC, facility.

The $252-million acquisition is expected to strengthen Cambrex’s position as a small-molecule CDMO across the drug lifecycle.

The Massachusetts site, formerly associated with an affiliate of Shire, is Rentschler Biopharma’s first facility in the US.

The merged companies will provide histopathology services in the research and pre-clinical therapeutics markets.

The contract research organization has increased its US-based early phase clinical capacity and doubled its specialty lab space.

ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.

With the $252-million acquisition of contract development, manufacturing, and testing organization Avista Pharma Solutions, Cambrex will enter the market for early stage small-molecule development and testing services.

In preparation for the upcoming US Drug Supply Chain Security Act deadline, Metrics Contract Services has expanded serialization capabilities at its oral solid-dose commercial manufacturing site in Greenville, NC.

Experts believe that the contract development and manufacturing organization market will reach $17.38 billion by 2022, with disruptive business models using Industrial Internet of Things (IIot) and single-use technologies proving more profitable and efficient in the long term.

Pharmatech Associates International Contracting and Services is a new company headquartered in Doha, Qatar, that will provide product development, facility design, and construction for high quality pharmaceutical and biotech products at low cost.

Idifarma, a contract development and manufacturing organisation (CDMO), based in Spain, has announced the commencement of the seventh project with Palobiofarma-a Spanish biotechnology company.

The contract development and manufacturing organization released its first serialized products to Europe from its facilities in Lisbon, Portugal and Stockholm, Sweden.

The new facility will include comprehensive mammalian process development and manufacturing capabilities.

Industry experts discuss the formulation and development issues that should be considered when addressing scale up from small-scale batches to commercial production.

The sterile-manufacturing contract development manufacturing organization is approved by FDA for viral vector manufacturing fill/finish processing at its biologics facility in Scotland, UK.

The contract development and manufacturing organization expanded its analytical chemistry suite and added a new office in Boston, MA.